Stock Events

Stock Events

XORTX Therapeutics 

0
0
+€0.00+0% 00:00 Today

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

12NovExpected
Q1 2026
Q2 2026
Next
-0.91
-0.77
-0.63
-0.5
Expected EPS
N/A
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-2.31MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow ANU1.MU. It's not an investment recommendation.
Iovance Biotherapeutics
4
IOVA
Aditxt
4
ADTX
ScanTech AI Systems
4
STAI
NVIDIA
3
NVDA

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Vertex Pharmaceuticals
VRTX
Mkt Cap137.3B
Vertex Pharmaceuticals is involved in developing treatments for cystic fibrosis and other diseases, potentially overlapping with XORTX's focus on kidney diseases and conditions that could have similar treatment approaches.
Aurinia Pharmaceuticals
AUPH
Mkt Cap2.17B
Aurinia Pharmaceuticals focuses on the development of therapies for autoimmune diseases, including lupus nephritis, which could compete with XORTX's kidney-focused therapies.
Akebia Therapeutics
AKBA
Mkt Cap243.47M
Akebia Therapeutics works on treatments for kidney disease and anemia, areas that overlap with XORTX's therapeutic focus, making them direct competitors.
Ardelyx
ARDX
Mkt Cap983.69M
Ardelyx focuses on kidney and cardiovascular diseases, offering treatments that could compete with XORTX's products for similar indications.
Trevena
TRVN
Mkt Cap9,501
Trevena develops therapies for central nervous system disorders but has potential overlap in treatment methodologies that could be applied to conditions XORTX targets.
Outlook Therapeutics
OTLK
Mkt Cap156.5M
Outlook Therapeutics is focused on ocular diseases but represents the broader competition in the biopharmaceutical sector, competing for investment and resources.

About

XORTX Therapeutics Inc is a clinical-stage pharmaceutical company focused on developing therapies to treat gout and progressive kidney disease modulated by aberrant purine and uric acid metabolism in orphan disease indications such as allopurinol-intolerant gout and autosomal dominant polycystic kidney disease, as well as more prevalent type 2 diabetic nephropathy and fatty liver disease. Its focus is on developing products to slow and/or reverse the progression of these diseases. The Company operates in one reportable operating segment: the development and commercialization of therapies to treat hyperuricemia-related diseases.
Show more...
CEO
Allen Warren Davidoff
Employees
3
Country
Canada
ISIN
CA98420Q1081

Listings

STU
DE
ANU.STU
MU
DE
ANU.MU
STU
DE
ANUA.STU
MU
DE
ANU1.MU

0 Comments

Share your thoughts

FAQ

What is XORTX Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Muenchen exchange XORTX Therapeutics stocks are traded under the ticker ANU1.MU.
When is the next XORTX Therapeutics earnings date?▼
XORTX Therapeutics is going to release the next earnings report on November 12, 2026.
What were XORTX Therapeutics earnings last quarter?▼
ANU1.MU earnings for the last quarter are -0.91 EUR per share, whereas the estimation was N/A EUR resulting in a N/A surprise. The estimated earnings for the next quarter are N/A EUR per share.
What is XORTX Therapeutics revenue for the last year?▼
XORTX Therapeutics revenue for the last year amounts to 0 EUR.
What is XORTX Therapeutics net income for the last year?▼
ANU1.MU net income for the last year is -2.31M EUR.
How many employees does XORTX Therapeutics have?▼
As of September 04, 2026, the company has 3 employees.
In which sector is XORTX Therapeutics located?▼
XORTX Therapeutics operates in the Health & Wellness sector.
When did XORTX Therapeutics complete a stock split?▼
The last stock split for XORTX Therapeutics was on September 23, 2021 with a ratio of 1:11.74.
Where is XORTX Therapeutics headquartered?▼
XORTX Therapeutics is headquartered in Calgary, Canada.